focus -WSS

focus

author：comprehensive 2025-10-02 18:05:48 - browse：41642

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here.

ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band. “Today is the greatest day I’ve ever known.” Also: “I’ll burn my eyes out before I get out.”

What if sometimes cancer doctors could give less medicine?

Are cancer drugs more likely to be cures? Or could they instead turn cancer into a chronic disease, in which medicines keep tumors in check but patients have to deal with their side effects, both physical and financial, for the rest of their lives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Former Pear Therapeutics executives start new VC firm

focus

WSS

Kellogg’s is going to war over Mexico’s nutrition label rules

Free medical tuition alone isn't enough to close gaps in primary care

FDA greenlights medical device to combat bladder issues

Oak Street deal isn't the answer to health care's woes

Oak Street deal isn't the answer to health care's woes

Obesity drug from Roche shows promise in early study

entertainment

focus

What if sometimes cancer doctors could give less medicine?

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Dobbs anniversary: the lost opportunity of abortion as health care

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hottest summer in 2,000 years puts focus on extreme heat, health

Psychedelics group wrestles with new pharma identity

Can U.S. cancer drug shortages be fixed?

Cancer drug shortages should be causing more outrage

Lilly’s weekly insulin works as well as daily products, new studies show

hotspot

People can get long Covid without testing positive for virus: Study

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Lilly’s weekly insulin works as well as daily products, new studies show

PBMs are inflating the cost of generic drugs. They must be reined in

Ripples from Flovent's discontinuation is killing children with asthma

Listen: Vivek Ramaswamy's star turn & leaky drug data

focus

hotspot

knowledge

knowledge